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Abstract
Introduction In Graves’ Ophthalmopathy, it is important to
distinguish active inflammatory phase, responsive to immuno-
suppressive treatment, from fibrotic unresponsive inactive one.
The purpose of this study is, first, to identify the relevant orbital
magnetic resonance imaging signal intensities before treatment,
so to classify patients according to their clinical activity score
(CAS), discriminating inactive (CAS<3) from active Graves’
Ophthalmopathy (GO) (CAS>3) subjects and, second, to fol-
low post-steroid treatment disease.
Methods An observational study was executed on 32 GO
consecutive patients in different phases of disease, based on
clinical and orbital Magnetic Resonance Imaging parameters,
compared to 32 healthy volunteers. Orbital Magnetic Resonance
Imaging was performed on a 1.5 tesla Magnetic Resonance Unit
by an experienced neuroradiologist blinded to the clinical
examinations.
Results In pre-therapy patients, compared to controls, a medial
rectus muscle statistically significant signal intensity ratio (SIR)
in short-time inversion recovery (STIR) (long TR/TE) sequence
was found, as well as when comparing patients before and after
treatment, both medial and inferior rectus muscle SIR resulted
significantly statistically different in STIR. These increased
outcomes explain the inflammation oedematous phase of dis-
ease, moreover after steroid administration, compared to con-
trols; patients presented lack of that statistically significant
difference, thus suggesting treatment effectiveness.
Conclusion In our study, we proved STIR signal intensities
increase in inflammation oedematous phase, confirming STIR
sequence to define active phase of disease with more sensi-
bility and reproducibility than CAS alone and to evaluate post-
therapy involvement.
Keywords Graves’Ophthalmopathy . Oedematous phase .
SIR in STIR
Introduction
Graves’ Ophthalmopathy (GO) is a chronic inflammatory
autoimmune disease of periorbital tissue and conjunctiva, as
well as of retrobulbar structures, e.g. extraocular muscles
(EOM). The most frequent GO clinical signs are eyelid ery-
thema, oedema, chemosis, upper eyelid retraction, proptosis
(exophthalmos), restricted ocular motility as well as sight-
threatening complications of compressive optic neuropathy
and corneal ulcerations. Clinical manifestations of GO are
evident and severe in only 3–5 % of patients. In fact, GO is
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more often characterized by subclinical course, and its pre-
sentation can be heterogeneous since not all features are
present in every patient [1–3].
The most important pathogenic factors are the human
thyroid-stimulating hormone receptor autoantibodies
(hTRAb). The autoimmune attack determines swelling of
the extra-ocular muscles in association with an increase in
orbital connective tissue and fat volume and consequent re-
strictive ophthalmoplegia [4, 5].
Two phases characterize the GO clinical course:
1. Active phase, histologically characterized bymononuclear-
cells infiltrations, proliferating fibroblasts, oedema and
enlargement of orbital muscles many times their normal
size;
2. Inactive or chronic phase, identified by fibrosis and fatty
infiltrations of muscles, causing the extension of fibrous
strands into adjacent adipose tissue [1, 6].
The distinct diagnosis of classical GO is based on clinical
presentation and laboratory results thus without the need for
any further imaging.
Four mandatory objectives should be taken into account in
the first evaluation of clinically suspected GO patients:
1. To support clinical diagnosis of GO by Imaging
2. To identify disease phase, in order to establish correct
treatment
3. To assess disease severity and, therefore, indication to
treatment
4. To follow post-treated disease
In this study, we have considered the validated scoring
system clinical activity score (CAS), proposed by Mourits
et al, to identify the disease phase distinguishing inflammatory
from non-inflammatory GO [7]. In agreement with the
European Groups on Graves’ Orbithopathy (EUGOGO) rec-
ommendations, CAS >3 defines active GO, thus responding
to radiotherapy with positive predictive value (PPV) of 65 %
and negative predictive value (NPV) of 56 % [7–9].
Moreover, another scoring system is the well-known
NOSPECS classification, first introduced by Werner in
1969, representing a summary of signs and symptoms further
modified in 1977. This classification system categorizes
thyroid-associated orbitopathy (TAO) patients in six different
classes and is still used today, although minor changes in
clinical disease, as well as active and quiescent phases of
TAO, are difficult to distinguish through NOSPECS criteria.
[10, 11].
The aim of this study is, first, to identify the most relevant
pre-treatment orbital MRI signal intensities, on short-time
inversion recovery (STIR)with long repetition time (TR)/echo
time (TE) and on contrast-enhanced T1 sequences with fat
saturation, performed within the same day of patient’s clinical
evaluation, so to best discriminate patients presenting a
CAS <3 (suspected non-inflammatory or inactive GO) from
patients with a CAS >3 (suspected inflammatory or active
GO) and, second, to follow post-treatment disease. Further,
diagnostic advantages in the evaluation of GO and improve-
ment of accuracy in the detection of the disease activity by
orbital MRI have also been described.
Materials and methods
Patients characteristics, protocols and clinical evaluations
Between October 2011 and November 2012, an observational
study was conducted on thirty-two diagnosed GO consecutive
patients (12males and 20 females, mean age of 56.81 years) in
different phases of thyroid disease, derived from clinical
(Table 1) and orbital MRI signs. These patients were exam-
ined after treatment too. Moreover, thirty-two normal volun-
teers (12 males and 20 females, mean age of 51.20 years) were
enrolled in the study, as control group. MRI signal intensities
ascertained from healthy volunteers played an important role
as they contributed to a more heterogeneous sample, allowing
robust results to be carried out.
The inclusion criteria were ocular symptomatology in pa-
tients exhibiting a proved history of Graves’ thyroid disease or
even confirmed by related clinical and laboratory signs and
above all presenting with bilateral manifestation. Healthy
volunteers showed normal MRI scans.
Exclusion criteria were orbit diseases such as trauma, optic
neuropathy, other inflammatory diseases of unknown origin,
previous orbital radiotherapy or surgery, previous immuno-
suppressive steroid and antithyroid treatments lasting more
than 12 weeks before MRI examination.
All patients, as well as volunteers, gave informed consent
to take part in the contrast-enhanced orbital MRI studies. The
protocol was approved by the local ethical board in our
hospital and therefore has been performed in accordance with
the ethical standards laid down in the Declaration of Helsinki.
Patients were clinically observed through CAS by two differ-
ent operators one by one (blind), assigning a rating for each
Table 1 Patients’ clinical and orbital MRI signs
Range (min–max) Median Reference values
TSH (UI/ml) 0.001–3.19 0.7 0.4–4.0
FT3 (pg/ml) 2.6–9.60 3.8 1.5–5.9
FT4 (pg/ml) 6.8–21.7 11.9 5.2–15.8
hTRAb (UI) 0.1–46 7.65 <1.5
Males 12 (37.5 %), females 20 (62.5 %)
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parameter and finally calculating the total score in relation to
the scheme in Table 2.
All patients were subjected to a 6-month MRI evaluation
follow-up, after a 3-month treatment consisting of intravenous
administration of metilprednisone 500 mg twice per day a
week for 12 weeks, followed by oral prednisone tapering
therapy for 2 months.
MRI analysis
All patients were subjected to Magnetic Resonance Imaging
within the same day of the clinical evaluation. Orbital MRI
was performed on a 1.5 tesla MRI unit (Magnetom
Symphony, Siemens Medical Systems, Erlangen, Germany)
with an Imaging protocol consisting of the following sequences:
axial turbo spin-echo (TSE) T2-weighted images (parameters:
repetition time/echo time/Nex=3350/116/2 with a 259×384
matrix, field of view (FOV) 240 mm and a 5-mm slice thickness
with no gap), axial fat-suppressed (FS) TSE T2-w images
(parameters: repetition time/echo time/Nex=3960/115/3 with a
248×320matrix, FOV 220 mm and a 4-mm slice thickness with
a 0.4 mm space between slices, inversion time 50 ms), coronal
fat-suppressed TSE T2-w images (parameters: repetition
time/echo time/Nex=3960/115/3 with a 248×320 matrix, FOV
210 mm and a 3.6-mm slice thickness with a 0.4-mm gap),
coronal fat-suppressed T1-w images, acquired on a plane per-
pendicular to the optic nerve (parameters: repetition time/echo
time/Nex=472/15/3 with a 448×512 matrix, FOV 210 mm and
a 3-mm slice thickness with no gap), and axial 3D fat-suppressed
T1-w volumetric interpolated breath-hold examination (VIBE)
images (parameters: repetition time/echo time/Nex=8/2,46/3
with a 205×256 matrix, FOV 200 mm, one slab with 52 slices
per slab and 1-mm slice thickness without gap).
Contrast-enhanced images were obtained immediately fol-
lowing intravenous (IV) administration of 0.1 ml/kg of gado-
butrol 1.0 mol (Gadovist, Bayer Schering Pharma, Berlin,
Germany) consisting of axial 3D fat-suppressed T1-w VIBE
images and coronal fat-suppressed T1-w images copying the
same parameters as the pre-contrast phase.
MRI scans were assessed by an experienced neuroradiolo-
gist blinded to clinical examinations.
Since GO most frequently involves the inferior and medial
rectus muscles, as demonstrated in literature [4, 6, 12], the
neuroradiologist positioned region of interests (ROIs)
avoiding the Magnetic inhomogeneity artifacts from the
bone/air of maxillary sinus. ROIs were drawn around the
inferior and medial rectus muscles on coronal acquisitions,
from anterior origin of the muscles to the orbital cavity apex,
considering the so-called ‘hot spot’ method [13] where hot
spot is defined as the highest-signal area within the most
inflamed muscle. The values in the highest-signal-intensity
area were calculated, and the resulting ‘average’ value [13]
was considered together with its corresponding standard de-
viations. This second method represents the mean signal in-
tensity over the whole cross section of the most inflamed
extra-ocular muscle at the hot spot. The most inflamed muscle
was selected as the one with the highest-signal intensity on
STIR sequence in MRI.
This evaluation was performed by positioning ROIs in the
same position before and after treatment. Thesemeasurements
were repeated two times to make results more reproducible,
thus showing no significant differences in the two evaluations.
Moreover, these measured signal intensities were set in
proportion to those of the ipsilateral temporal muscle to cal-
culate the signal intensity ratio (SIR), a more objective and
reproducible indicator. The temporal muscles were considered
as reference standard since they are not involved in Graves’
disease and because of their structural similarity and close
anatomical relationship to the EOM (Figs. 1, 2, and 3) [4, 6].
Therefore, a wide number of single-muscle variables were
obtained in both patient and volunteer groups considering SIR
related to FS T2- and to gadolinium-enhanced FS T1-
weighted images.
Statistical analysis
Statistical analysis was performed using SPSS 20 (Statistical
Package for Social Science) software.
All MRI signal intensities were reported as mean standard
deviation (SD), and both examined muscle signal intensity
ratio (SIR) referred to the ipsilateral temporal one were point-
ed out.
CAS, STIR and enhanced T1 inferior and medial rectus
muscle signal intensity ratios, normalized to ipsilateral tem-
poral muscle, were evaluated on group analysis, using the
paired samples t test, before and after treatment. The same







Spontaneous orbital pain 0–1
Gaze evoked orbital pain 0–1
Clinical activity score (CAS) (amended by EUGOGO after Mourits et al
[7]): 1, spontaneous orbital pain; 2, Gaze evoked orbital pain; 3, eyelid
swelling that is considered to be due to active (inflammatory phase) GO; 4,
eyelid erythema; 5, conjunctival redness that is considered to be due to
active (inflammatory phase) GO; 6, chemosis; 7, inflammation of caruncle
OR plica; 8, increase of >2 mm in proptosis; 9, decrease in uniocular
ocular excursion in any one direction of >8°; 10, Decrease of acuity
equivalent to 1 Snellen line. For initial CAS, only score items 1–7; Patients
assessed after follow-up can be scored out of 10 by including items 8–10
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parameters entered into the Correlation Analysis and were
performed using the Spearman test.
Moreover, a Multiple Regression Analysis was assessed
considering MRI measurements as variables to estimate the
most significant predictive value resulting from the examined
Magnetic Resonance sequences.
A p value of <0.05 was considered as significant.
Results
Among the thirty-two GO patients, most presented over 3
points CAS (n=31), while only one had a less 3 points CAS
(n=1). Those patients with CAS >3 presented a range value
from 3 to 5 mean (M)±standard deviation (SD), 4.4±0.68.
Obviously, all thirty-two normal volunteers had a CAS
value of 0.
From now onwards, we refer to each MRI signal intensity
according to its short notation (Table 3), arbitrary defined for
statistical analysis. Table 4 (paired samples test) shows the
means, standard deviations (SD) and confidence interval of
difference of MRI pre- and post-therapy signal intensities
studied in GO patients and controls as well as their full
interchange.
In our group, most of the examined patients (n=31)
showed post-treatment regressive symptoms, clinically evalu-
ated and proved by the correlated CAS range value included
between 1 and 4 (2.58±0.72).
When comparing pre versus post-treated patients, medial
rectus signal intensity ratios (SIR) from cross-sectional area
on enhanced T1 sequence (Pre_Rmed SIR T1 + c.a.) resulted
significantly higher (p≤0,038) than post-treatment SIR (Post_
Rmed SIR T1 + c.a.), also, pre-therapy medial rectus muscle
SIR measured in STIR (Pre_Rmed STIR SIR) resulted signif-
icantly increased SIR (p≤0.001) than the post-therapy SIR
(Post_ Rmed STIR SIR), as well as inferior pre-treated group
rectus muscle signal intensity ratios (p≤0.00001) in STIR
(Pre_Rinf STIR SIR) were higher than that of the post-
treated one (Post_ Rinf STIR SIR).
Comparing pre-therapy patients to controls (Fig. 4), medial
rectus cross-sectional area SIR in STIR (Pre_Rmed STIR SIR)
resulted significantly higher SIR (p≤0.0002) together with
Fig. 1 Coronal T2 FS image
showing ROI on extraocular
muscles
Fig. 2 Coronal FS
T1-unenhanced image showing
ROI on bilateral inferior and
medial rectus muscles
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more significantly increased (p≤0.002) inferior rectus muscle
SIR (Pre_Rinf STIR SIR); similarly, on enhanced T1 se-
quence, medial rectus SIR significantly increased
(Pre_Rmed SIR T1 + c.a. ; p≤0.00001) as well as the inferior
rectus muscle SIR (Pre_Rinf SIR T1 + c. a. ; p≤0.00001).
Comparing treated patients to controls, the enhanced T1
medial rectus cross-sectional area SIR (Post_Rmed SIR T1 +
c.a.) was found significantly higher (p≤0.0004) than the one
(Norm_Rmed SIR T1 + c. a.) in volunteers; similarly, results
are derived from Post_Rinf SIR T1 + c. a., showing a higher
statistical value (p≤0.0003) than the one in controls
(Norm_Rinf SIR T1 + c. a.). However, when compared to
controls, no statistical significance was derived between both
post-treatment STIR medial and inferior rectus muscle SIR
(Post_Rmed STIR SIR, p≤0.238; Post_Rinf STIR SIR, p≤
0.642) and the related SIR in volunteers.
In the pre-therapy group, medial and inferior rectus muscle
CAS values significantly correlated with corresponding SIR
mean values both on enhanced T1 and STIR sequence, as
showed respectively for Pre_Rmed SIR T1 + c.a. (p<0.007),
Pre_Rinf SIR T1 + c. a. (p<0.002), Pre_Rmed STIR SIR
(p<0.001) and Pre_Rinf STIR SIR (p<0.017). Moreover,
MRI STIR medial and inferior rectus muscle signal intensities
significantly correlated with the equivalent intensities on
enhanced T1 sequence (SIR T1 + c. a., p<0.002); data not
detected after treatment.
Furthermore, it was ascertained that Rmed STIR SIR had
the highest discriminatory power of 0.905 (95 %, confidence
interval (CI)=[0.828–0.982]) in classifying CAS >3 pa-
tients, acquiring both high sensitivity and specificity (SE 1.00
and SP 0.78), at the optimal cut-off of 2.23, whilst Rinf SIR T1
+ c.a. had a discriminatory power of 0.843, (95 %,
CI=[0.745–0.941]), acquiring a sensitivity of 0.75 and a
specificity of 0.78, at the optimal cut-off of 1.71.
Table 5 shows all the MRI signal discriminatory powers
and the related optimal cut-off.
Therefore, a patient presenting a Rmed STIR SIR ≥2.23
would be classified into CAS >3 group, only with one wrong
classification (false-positive) on five measurements; however,
even if Rinf SIR T1 + c.a. showed the same specificity, its
sensibility of 75 % may be considered unsatisfying.
By defining the ‘stepwise’ procedure based on the multiple
linear regression model, Rmed STIR SIR and Rmed SIR T1 +
c.a. presenting a multilinear regression coefficient of R=0.3907
(standard error 0.167) and R=1.07 (standard error 0.517) were
found to be the most significant predictors.
Moreover, D’ Agostino-Pearson test on residuals resulted
insignificant (p=0.9931, multiple correlation coefficient of
0.63), suggesting a very good model fitting and the respect
of normality assumption. After therapy, CAS values ranged
from 1 and 4 (M=2.58 and SD=0.72).
Discussion
Symptomatic patients presenting the active phase of disease
more often report dry and gritty ocular sensation, photopho-
bia, excessive tearing, double vision and a pressure sensation
behind the eyes. Moreover, suddenly appeared or modified
altered appearance and double vision are specific for active
disease. Particularly, worsening on waking, eventually
Fig. 3 Coronal FS T1-enhanced
image showing ROI on inferior
and medial rectus muscles
Table 3 List of MR signal notations
Rinf STIR SIR Signal intensity ratio in STIR sequences
in inferior rectus muscle
Rmed STIR SIR Signal intensity ratio in STIR sequences in
medial rectus muscle
Rinf SIR T1+ c.a. Enhanced T1 signal intensity ratio of the inferior
rectus muscle
Rmed SIR T1 + c.a. Enhanced T1 signal intensity ratio of the medial
rectus muscle
c.a. Contrast agent
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painful, intermittent diplopia is strongly suggestive of active
GO. Permanent alterations in visual functions, such as blurred
vision or altered colour perception, are potential markers of
dysthyroid optic neuropathy (DON), determining optic nerve
compression in the orbital apex.
Early diagnosis has primary importance in GO manage-
ment, avoiding permanent injuries to the patients (proptosis,
sight impairment). Medical corticosteroid therapies in early
stages of disease reduce the inflammation and let the GO
remission, though useless in fibrotic end-stages. So, early
diagnosis and treatment would cause at least partial remission,
up to 65 % of cases [14].
The CAS scoring system evaluates disease activity and
response to immunosuppressive therapy but actually does
not fully describe the overall status of GO [3, 15]. This method
is widely used through the reported correlation between pre-
treatment CAS and post-immunomodulating therapy outcome
(retailed positive predictive value of 80 % and negative pre-
dictive value of 64 % [16]). Anyway, Mourits’ study never
demonstrated CAS <3 patients having inactive GO [7, 15],
especially since in Mourits’ report, 10 of 13 CAS <3 patients
responded to immunosuppressive treatment [3, 15, 17] there-
fore showing that CAS alone could not detect active GO
adequately [15].
Significant CAS limits consist in the lack of evaluation of
various inflammation levels as well as its operator-dependent
low sensibility and subjectivity [2, 5, 15]. Furthermore, the
score attributes the same value to various different factors,
thus missing diversifications. Therefore, CAS requires the
integration with other modalities [15, 18, 19], as orbital
Table 4 Paired samples test
Pairs Differences t DF p (two-tailed)
Mean SD Standard error
of the mean
95 % Confidence interval
of the difference
Lower Upper
1 Pre_RmedSIRT1 + c.a. and Post_Rmed SIR T1 + c.a. −,24 ,63 ,11 −,47 −,01 −2,16 31 ,038
2 Pre_Rinf SIR T1 + c.a. and Post_Rinf SIR T1 + c.a. −,20 ,63 ,11 −,43 ,023 −1,83 31 ,076
3 Pre_Rmed STIR SIR and Post_Rmed STIR SIR 1,10 ,92 ,16 ,77 1,43 6,77 31 ,001
4 Pre_Rinf STIR SIR and Post_Rinf STIR SIR ,73 ,80 ,14 ,44 1,02 5,15 31 ,00001
5 Pre_Rmed SIR T1 + c.a. and Norm_Rmed SIR T1 + c.a. ,35 ,46 ,08 ,18 ,52 4,29 31 ,00001
6 Pre_Rinf SIR T1 + c.a. and Norm_Rinf SIR T1 + c. a. ,36 ,42 ,07 ,21 ,51 4,81 31 ,00001
7 Pre_Rmed STIR SIR and Norm_Rmed STIR SIR 1,24 1,18 ,21 ,81 1,67 5,91 31 ,0002
8 Pre_Rinf STIR SIR and Norm_Rinf STIR SIR ,80 1,3 ,23 ,33 1,27 3,47 31 ,002
9 Post_Rmed SIR T1 + c.a. & Norm_Rmed SIR T1 + c.a. ,60 ,61 ,12 ,38 ,81 5,55 31 ,0004
10 Post _Rinf SIR T1 + c.a. and Norm_Rinf SIR T1 + c.a. ,56 ,55 ,10 ,37 ,76 5,81 31 ,0003
11 Post _Rmed STIR SIR and Norm_Rmed STIR SIR ,14 ,64 ,11 −,10 ,37 1,20 31 ,238
12 Post _Rinf STIR SIR and Norm_Rinf STIR SIR ,07 ,82 ,14 −,23 ,36 ,47 31 ,642
Pre_ Pre-treatment patients, Post_ post-treatment patients, Norm_ healthy volunteers, DF degree of freedom
Fig. 4 Coronal T2 FS image after
corticosteroid therapy showing
ROI on extraocular muscles
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ecography and CT/MRI to determine disease activity and
severity [20].
Orbital CT is useful in detecting extra-ocular muscle en-
largement and proptosis degrees, but not muscle composition
and the inflammation phase; moreover, consequent crystalline
irradiation prevents its use in follow-up.
Computed tomography (CT) is an invaluable Imaging mo-
dality in the evaluation of TAO, using X-rays and their vari-
able absorptions within the many orbital structures to quantify
and qualify orbital pathologies. CT as a tool to quantify
muscle enlargement, similar to ultrasound (US), is therefore
a valuable aid to the clinical exam. Studies suggest parallels
between total extraocular muscle volumes and medial rectus
muscle width at the mid-orbital level, and medial rectus mus-
cle width with clinical extraocular muscle restriction,
periorbital oedema, and optic neuropathy in those with TAO.
Unlike US and MRI, CT involves radiation and cannot pre-
cisely assess disease activity, in fact, even if oedema of extra-
ocular eye muscles or of intra-orbital or periorbital can be
recognized, oedema involving optic nerve is not detected. CT,
however, remains a fast, available, relatively inexpensive, and
highly reproducible test, although the possible assessment of
the optic nerve itself is less specific than that of MRI. Contrast
administration is oftentimes reserved, then, for cases of optic
nerve pathology or vision loss [21]. Moreover, after iodinated
contrast agent administration, CT can show an active inflam-
mation, but since the hyperthyroid metabolism of many pa-
tients, contrast administration should be avoided (27).
Instead, MRI gives all the information of both ecography
and CT, discovering muscle oedema, because of its intrinsic
capability to characterize tissue. Many recent studies are vali-
dating the utility of MRI in GO because of detailed orbital
anatomy Imaging (characterizing high soft tissue, through thin
sections and multiplanar reconstructions), lack of ionizing ra-
diation and examination reproducibility. So the ability to dif-
ferentiate inflammatory from fibrotic orbital tissue alterations
allows to choose the right treatment; moreover, Imaging is
always required in doubtful cases to exclude any other pathol-
ogy and in evaluating the clinical suspicion of optic nerve
involvement, thus to plan orbital decompression [12].
Anyway, as already described, classical GO presentation does
not need any further distinct Imaging finalized to diagnosis.
In GO, the standardized MRI protocol includes fast spin-
echo T1-w and T2-w STIR sequences on 3-mm slice thickness
transverse and coronal planes [12].
In our study, when comparing pre-treated patients to con-
trols, medial and inferior rectus muscle intensities were sig-
nificantly different in both STIR (Rmed STIR SIR, p=0.0002;
Rinf STIR SIR, p=0.002) and enhanced T1 sequences (Rmed
SIR T1 + c.a., p=0.00001; Rinf SIR T1 + c.a., p=0.00001).
This result attests the utility of these sequences in detecting
extra-ocular muscle oedema, especially referring to the relax-
ation T2 time found longer than in healthy controls [5, 15, 22],
confirming EOM inflammatory involvement [1–4, 12, 13]
occurring earlier than ocular symptomatology, as well as
showing at least one EOM MRI involvement in 50 % of
patients on subclinical phase [23].
Furthermore, in the pathologic group, both muscle SIRs in
STIR sequence significantly correlated with enhanced T1 one
(p=0.002), leading to suppose STIR to be the handler than
enhanced T1, thus interestingly avoiding contrast medium.
Moreover, medial rectus muscle signal intensity ratio in
STIR sequence (Rmed STIR SIR) was found to be the most
capable MRI parameter to assign a subject to CAS <3 or CAS
>3 group at the optimal cut-off value of 2.23, then, presenting
the highest proportion of identified actual positives
[Sensitivity (SE) 1.00] and the lowest proportion of false
positives [high Specificity (SP) 0.78].
MRI is able to differentiate the two disease states, demon-
strating extraocular muscle interstitial oedema on coronal
STIR sequences in the active disease.
Inflamed extraocular muscle signal intensity is known to
correlate with CAS, therefore having a strong impact on the
two treatment options: immunosuppressants or surgery [12,
15, 22, 24]. CAS alone could not detect active GO sufficiently,
and orbital MRI could predict the response to corticosteroid
therapy more accurately than CAS alone [15]. Although the
‘fine tune’ of thyroid values is often enough, management of
GO is mainly based on three treatment arms:
1. Treatment of the underlying dysthyroid disease and main-
tenance of a euthyroid state (anti-thyroid drugs, total
thyroidectomy, and/or 131radioiodine)
2. Immunosuppression with high-dose corticosteroids and/
or orbital radiotherapy
3. Surgery (sequential orbital decompression, squint and lid
surgery)
Moreover, T2 sequence lets us observe therapeutic effect
[25]; as found in our study, when comparing steroid-treated
Table 5 Discriminatory power
and diagnostic test characteristics MRI measurements AUC [95%CI] Optimal cut-off Sensibility (SE) Specificity (SP)
Rinf STIR SIR 0,756 [0.637–0.875] 1.79 1.00 0.50
Rmed SIR STIR 0,905 [0.828–0.982] 2.23 1.00 0.78
Rinf SIR T1 + c.a. 0,843 [0.745–0.941] 1.71 0.75 0.78
Rmed SIR T1 + c.a. 0,794 [0.683–0.905] 1.91 0.50 0.97
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patients to controls, in fact, both medial and inferior rectus
muscle signal intensities on STIR did not show any statisti-
cally significant difference, confirming therapy effectiveness;
anyway, this result is in contrast with the increase in both
muscle different signal intensities on enhanced T1. This out-
come could be justified by the unclear role of T1 sequence
contrast enhancement of EOMs in GO acute inflammatory
stage, determined by the multitude of pathogenetic factors
(microcirculation injury due to muscle enlargement and in-
flammatory infiltration versus vascular congestion, caused by
oedema and interstitial inflammatory infiltration [4, 6, 10,
11]), thus leading to the diagnostic accuracy of STIR se-
quences in detecting both active and inactive phases, with
the outstanding advantage of avoiding contrast injection.
Eye muscle oedema is observed in the subclinical stage
of the disease, usually characterized by eyelid retraction,
larger lid fissure and decreased eyelid impact frequency.
This leads to the great aim to detect those patients at risk
and responders to immunosuppressive treatment in early
and even pre-clinical stages in order to prevent progres-
sion and deterioration of pre-clinical GO. The diagnosis
actually relies on the well-known risk factors like history,
symptoms, clinical signs, smoking, and serology for the
development or deterioration of GO. Therefore, a MRI
SIR cut-off value is considered an ‘objective’ method able
to enhance the reliability of these risk factors. From our
data, we statistically calculated a cut-off value of 2.23 for
a CAS ≥3, which usually defines active GO.
As reported in literature, the existence of subclinical stage
of this condition is well known, but in our study, patients
presented bilateral clinical signs, so they could not be consid-
ered in this pathological phase. Moreover, as previously de-
scribed in the pre-therapy group, medial and inferior rectus
muscle CAS values significantly correlated with correspond-
ing SIR mean values both on enhanced T1 and STIR
sequence.
The valid indication of MRI supporting clinical assessment
in classical presentation of GO is represented by the possibil-
ity to determine disease activity in particularly severe cases.
Many recent studies are validating the utility of MRI in GO
because of detailed orbital anatomy Imaging (characterizing
high soft tissue, through thin sections and multiplanar recon-
structions), lack of ionizing radiation and examination repro-
ducibility [12].
Response to immunosuppressive therapy in correlation to
MRI derives from the previously described T2 sequence able
to show immunosuppressive therapeutic effect [15, 25]. In
fact, in our study, we proved that both the medial and inferior
rectus muscle signal intensities on STIR did not show any
statistically significant difference when comparing steroid
treated patients to controls, thus confirming therapy effective-
ness. Moreover, the significant improvement after treatment
demonstrates that orbital MRI imaging combined with CAS
can detect active GO more sensitively than CAS alone, and
also predict the response to IV or oral GC for GO more
accurately than CAS alone. This leads to the main role of
MRI in follow-up, to control the muscle signal intensity
changes related to therapeutic effect.
From the clinical findings and orbital imaging, we know
that in GO, inferior and internal EOMs are more frequently
involved than the superior, lateral, and oblique muscles. In our
study, when comparing to controls, a significant statistical
difference resulted from pre-treated medial and inferior rectus
muscle towards the non-pathologic ones in both STIR and
enhanced T1 sequences, thus explaining the utility of the
relaxation T2 time [5, 15, 22], confirming EOM inflammatory
involvement [1–4, 12, 13] occurring earlier than ocular
symptomatology.
Furthermore, in the pathologic group, medial rectus muscle
signal intensity ratio in STIR sequence (Rmed STIR SIR) was
found to be the most capable MRI parameter to assign a
subject a CAS >3 group at the optimal cut-off value of 2.23,
leading to its interpretation as the most significant muscle
intensity to refer to.
Our study is not without limitations. The first one is the
reproducibility of the data, due to the signal dependence on
specific MRI equipment. This limit could be in part overcome
because of the evaluation of signal intensity ratio in STIR,
assessed by means of a robust statistical method. Furthermore,
since SIR represents a more objective and reproducible mea-
sure, our statistical comparison results are more reliable.
Therefore, one of the study priority is actually represented
by the reproducibility improvement and the development of
orbital tissue evaluation common scale, even on differentMRI
equipment. The second one is represented by Imaging data
elaboration executed by only one neuroradiologist, placing
ROIs in pre- and post-treatment MRI.
Conclusion
In our study, we proved that STIR signal intensities increase in
inflammation oedematous phase of disease even though on
T1-w images, gadolinium contrast enhancement in combina-
tion with fat saturation represents a helpful tool to detect
extraocular muscle or eyelid intense enhancement [6, 12,
26]. So we bear out MRI STIR sequence to establish activity
phase of disease with more sensibility and reproducibil-
ity than CAS alone [15] and to evaluate post-therapy EOM
involvement, supported by the related obtained optimal cut-
off of 2.23.
As recommended by Cakirer et al. [6], our report contrib-
utes to improve the use of this technique to predict the sever-
ity, type of treatment, and prognosis of the disease.
In conclusion, our study supports the diagnostic accuracy of
STIR signal intensity ratios in identifying active inflammatory
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changes as well as in assessing follow-up and the treatment
response, implementing MRI capability, so underlining its
well-known lack of ionizing radiation and above all the proved
contrast medium sparing, in order to fit Imaging together with
clinical evaluation in a more evident way.
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